Evaluation of the Prognostic Impact of Decreased Serum beta2 Microglobulin in the First Year of Follow-up of Myeloproliferative Neoplasia (PRODIGE)
Active, not recruiting
- Conditions
- Myeloproliferative Neoplasm
- Registration Number
- NCT06553638
- Lead Sponsor
- University Hospital, Brest
- Brief Summary
50 patients with a diagnosis of MPN will have an assessment of b2microglobuline at diagnosis and after 1 year. b2mic value decrease will be compared to treatment response.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
- MPN patient diagnosed at one of the participating centers
- over 18 yo
Exclusion Criteria
- Not able to consent
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method b2mic decrease level between responders and non-responders 1 year
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Chu Brest
🇫🇷Brest, France